Search hospitals > Manitoba > WINNIPEG

Wiseman Dermatology Research Inc.

Claim this profile
WINNIPEG, Manitoba R3M 3Z4
Global Leader in Dermatitis
Global Leader in Atopic Dermatitis
Conducts research for Medical Device Dermatitis
Conducts research for Psoriasis
Conducts research for Periprosthetic Bone Loss
56 reported clinical trials
2 medical researchers
Photo of Wiseman Dermatology Research Inc. in WINNIPEGPhoto of Wiseman Dermatology Research Inc. in WINNIPEGPhoto of Wiseman Dermatology Research Inc. in WINNIPEG

Summary

Wiseman Dermatology Research Inc. is a medical facility located in WINNIPEG, Manitoba. This center is recognized for care of Dermatitis, Atopic Dermatitis, Medical Device Dermatitis, Psoriasis, Periprosthetic Bone Loss and other specialties. Wiseman Dermatology Research Inc. is involved with conducting 56 clinical trials across 33 conditions. There are 2 research doctors associated with this hospital, such as Marni Wiseman and Marni Charlotte Wiseman.

Top PIs

Clinical Trials running at Wiseman Dermatology Research Inc.

Alopecia Areata
Atopic Dermatitis
Dermatitis
Hidradenitis Suppurativa
Periprosthetic Bone Loss
Medical Device Dermatitis
Neutrophilic Eccrine Hidradenitis
Eczema
Hairy Birthmarks
Hypersecretion
Image of trial facility.

Ritlecitinib

for Alopecia Areata

The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata. Alopecia areata is a disease that causes hair loss on the scalp, face, and areas of the body. Ritlecitinib is approved in many countries at a dose of 50 mg (milligram) taken by mouth once a day for the treatment of patients 12 years and older with severe alopecia areata. This study will look at both the 50 mg dose and a 100 mg dose. This study is seeking participants who: * Are 12 years of age or older * Have a diagnosis of alopecia areata * Have lost 50% or more of the hair on their scalp * Do not have any other conditions that causes hair loss * Are willing to stop all other treatments that they may be taking for alopecia areata About 550 participants will take part in in this study. Participants will be chosen by chance, like drawing names out of a hat, to receive 1 of 2 different amounts of ritlecitinib (50 mg and 100 mg) taken by mouth once daily. The 2 doses of ritlecitinib in this study will be compared to each other and also to data from previous studies. This will help to see if the 100 mg dose of ritlecitinib is safe and effective. People will be in this study for about 13 months. During the study, participants will need to visit the study site up to 9 times. Participants will undergo various tests and procedures such as: * alopecia areata assessment, * physical examinations, * hearing tests, * blood tests, * x-ray, * ECG (electrocardiogram), * photographs of the scalp and eyes. Participants will also be asked to complete questionnaires about their alopecia areata.
Recruiting1 award Phase 32 criteria
Image of trial facility.

Baricitinib

for Pediatric Hair Loss

This trial is testing baricitinib, a medication that may help treat severe hair loss. It targets children aged 6 to less than 18 years who have significant hair loss. The medication works by reducing the immune system's activity that causes hair loss.
Recruiting1 award Phase 35 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Wiseman Dermatology Research Inc.?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security